Skip to content
Screener

Eli Lilly LLY Payments to Acquire in Process Research and Development

Payments to Acquire in Process Research and Development at other companies

Exelixis logo
ExelixisEXEL
$2.5M+233%

Other financials

Income statement

See full
Revenue$23.0B+47.7%
Gross profit$19.7B+50.3%
Net income$7.1B+25.3%
EPS (diluted)$7.94+26.2%

Balance sheet

See full
Cash & equivalents$9.0B+165%
Total debt$54.9B+37.6%
Total equity$33.9B+85.4%
Total assets$142.28B+41.0%

Cash flow

See full
Operating cash flow$10.7B+246%
CapEx$2.9B+72.8%
Free cash flow$7.8B+458%

Valuation

See full
Market cap$1.1T+95.8%
Enterprise value$1.14T+91.5%
P/E41.1×+0.5×
P/S13.8×+3.3×

Profitability

See full
Gross margin83.4%+0.8pp
Net margin33.5%+7.6pp
FCF margin22.8%+13.7pp

Returns & leverage

See full
Return on equity102.4%+15.7pp
Debt / equity1.6×-0.6×
Current ratio1.4×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.

The source filing: Eli Lilly’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:40 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000059478-26-000081
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Cash Flows from Investing Activities
Purchases of property and equipment(5,259)(3,207)
Purchases of noncurrent investments(604)(368)
Purchases of in-process research and development(3,486)(1,864)
Cash paid for acquisitions, net of cash acquired(9,805)—
Other investing activities, net(158)252
Net Cash Used for Investing Activities(19,312)(5,187)
Cash Flows from Financing Activities

Item 1. Financial Statements

FAQ

What is Eli Lilly's payments to acquire in process research and development?
Eli Lilly (LLY) reported payments to acquire in process research and development of $3.28B in Q2 2026.
How has Eli Lilly's payments to acquire in process research and development changed year-over-year?
Eli Lilly's payments to acquire in process research and development increased by 2967.3% year-over-year, from $107M to $3.28B.
What is the long-term trend for Eli Lilly's payments to acquire in process research and development?
Over 3 years (2021 to 2025), Eli Lilly's payments to acquire in process research and development has grown at a 65.1% compound annual growth rate (CAGR), from $668.6M to $3.01B.
What does payments to acquire in process research and development mean?
Payments to Acquire in Process Research and Development

Ask your AI about Eli Lilly's payments to acquire in process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude